Global Brain Disease Market Overview:
Brain disease is a type of central nervous system diseases. It refers to disabilities that affect the brain. There are various disability condition present in the brain disease such as brain deterioration, neurodegenerative diseases such as Alzheimer’s, Huntington’s disease and others. There are various symptoms of brain diseases such as headache, memory loss, tremors, increased reflexes, slurred speech, paralysis, and inability to concentrate among others. Surgery, radiation therapy, targeted therapy, chemotherapy and immunotherapy are the various treatment types used for brain disease. Some of the key players profiled in the study are Pfizer Inc. (United States), Eli Lilly (United States), F. Hoffmann La Roche AG (Switzerland), GE Healthcare (United States), Abbvie Inc. (United States), AC Immune SA (Switzerland), Allergan PLC (Ireland), Merck & Co (United States), Novartis AG (Switzerland) and AstraZeneca plc (United Kingdom).
On the basis of geography, the market of Brain Disease has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Hospitals Pharmacy will boost the Brain Disease market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis Type, the sub-segment i.e. CT Scan will boost the Brain Disease market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment Type, the sub-segment i.e. Surgery will boost the Brain Disease market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Drivers
- Increasing Awareness of Brain Diseases and Their Treatments
- Reducing Prices of Some Brain Disease Treatment
Market Trend
- Rising Government Support for Improving Healthcare System
- Technological Advancement Related to Brain cancer
Restraints
- Contrary Effects with the Medications
- Unfavorable Compensation Policies
Opportunities
- Increasing Health Care Expenditure in Developing Country
- Escalating Therapeutic Applications of Brain Monitoring Devices
Major Market Developments:
On 23rd October 2018, Pfizer a leading American pharmaceutical corporation headquartered in New York City and Bain Capital has came together to create new neuroscience-focused company.
On 24th November 2018, GE Healthcare has launched new applications and smart devices built on Edison. AIRx* is an AI-based, automated workflow device for MRI brain scanning designed to rise steadiness and productivity. On 4th January 2018, Pfizer has launched iTeos Therapeutics regained rights to its Phase I brain cancer drug.
Target Audience:
Healthcare Research laboratories, Pharmaceuticals Industries, Medical Institutes, Medical Devices Manufactures, Medical Devices Distributors, Government Regulatory Bodies, Government Research Organizations, Private Research Organizations and Others
Major Objectives Focused through this Study
To define, describe, and forecast the Global Brain Disease market on the basis of product [Brain Cancer, Alzheimer Disease, Alcoholism, Amnesia, Epilepsy, Meningitis and Others] , application [
], key regions and end user
To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
To provide market size for various segments of the Brain Disease market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
To strategically profile the key players and analyzing their market shares and core competencies in the Brain Disease industry
To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market
Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Medtronic, Inc. (Ireland), Boston Scientific Corporation (United States), Delmar Pharmaceuticals Inc. (United States) and Omeros Corporation (United States).
** Confirmation on availability of data would be informed prior purchase
While framing the research framework, major and emerging players operating in the Brain Disease market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.